Zydus Worldwide DMCC
As of the edition of 20 October 2026, Zydus Worldwide DMCC runs 21 drugs, 12 of them marketed; it is on route A at 7 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 7 company names in this family.
- Zyla Life Sciences Us Inc: acquired in 2020; successor Assertio Holdings, Inc.
- NeoTherapeutics: acquired in 2023; successor Zydus Worldwide DMCC
- Spectrum Pharmaceuticals, Inc: acquired in 2023; successor Assertio Holdings, Inc.
- Assertio Holdings, Inc.: acquired in 2026; successor Zydus Worldwide DMCC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Active | 1 |
| Went quiet | 3 |
| Stopped | 5 |
| Total | 21 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluorouracil | none listed | 2 |
| Melphalan | none listed | 0 |
| Morphine | none listed | 2 |
| Sitagliptin | Ends 2026 (patent) | 1 |
| Oxycodone | none listed | 2 |
| Diclofenac | none listed | 7 |
| Indomethacin | none listed | 3 |
| Belinostat | Ended 2026 (patent) | 0 |
| Levoleucovorin | none listed | 0 |
| Pralatrexate | none listed | 3 |
| Ibritumomab tiuxetan | Ended 2014 (computed from the first US licence) | 1 |
| Eflapegrastim | Ends 2034 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 7 targets, route B at 1 target.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where Zydus Worldwide DMCC needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 31 trials led
- Blood and lymph: 11 trials led
- Skin and connective tissue: 9 trials led